RT journal article
T1 Modifications of liver stiffness and CXCL4, TGF-beta 1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
A1 Márquez Coello, María de las Mercedes
A1 Arizcorreta Yarza, Ana
A1 Rodríguez Pardo, María
A1 Illanes Álvarez, Francisco
A1 Márquez, Denisse
A1 Cuesta Sancho, Sara
A1 Girón González, José Antonio
A2 BiomedicinaBiotecnología y Salud Pública
A2 Medicina
AB The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n=20), HIV/HCV-co-infected (n=66) patients and healthy controls (n=15). Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and serum concentrations of profibrotic transforming growth factor (TGF)-beta 1 and CXC chemokine ligand 4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) and 12 months after starting DAAs (M12). A M12 LS achievement of <= 9.5 kPa was considered the cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant differences were observed in LS decline between HCV- and HIV/HCV-infected individuals. Changes of serum CXCL4, TGF-beta 1 and HGF levels did not correlate with LS improvement. 16 out from 56 patients (28%) with a baseline LS>9.5 achieved a M12 LS <= 9.5. HCV-monoinfected and HIV/HCV coinfected patients experienced a significant reduction of LS after sustained virological response. This improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of those with a baseline LS>9.5 achieved a LS under this cutoff point.
PB NATURE RESEARCH
SN 2045-2322
YR 2021
FD 2021-05
LK http://hdl.handle.net/10498/25327
UL http://hdl.handle.net/10498/25327
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 12-nov-2026